Wong NS - Search Results

1

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB. Liu Y, et al. Among authors: wong ns. Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6. Cancer Med. 2013. PMID: 23634291 Free PMC article. Clinical Trial.

2

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

Wong NS, Fernando NH, Nixon AB, Cushman S, Aklilu M, Bendell JC, Morse MA, Blobe GC, Ashton J, Pang H, Hurwitz HI. Wong NS, et al. Anticancer Res. 2011 Jan;31(1):255-61. Anticancer Res. 2011. PMID: 21273607 Free PMC article. Clinical Trial.

3

A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.

Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. Wong NS, et al. Clin Colorectal Cancer. 2011 Sep;10(3):210-6. doi: 10.1016/j.clcc.2011.03.018. Epub 2011 Apr 24. Clin Colorectal Cancer. 2011. PMID: 21855046 Free PMC article. Clinical Trial.

4

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI. Wong NS, et al. Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912. Cancer Invest. 2011. PMID: 22011284 Free PMC article. Clinical Trial.

5

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H. Saladores P, et al. Among authors: wong ns. Pharmacogenomics J. 2015 Feb;15(1):84-94. doi: 10.1038/tpj.2014.34. Epub 2014 Aug 5. Pharmacogenomics J. 2015. PMID: 25091503 Free PMC article.

6

Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.

Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME. Wong NS, et al. Breast Cancer Res Treat. 2006 Sep;99(1):63-9. doi: 10.1007/s10549-006-9181-4. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541316

7

The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients.

Lee CF, Ng R, Luo N, Wong NS, Yap YS, Lo SK, Chia WK, Yee A, Krishna L, Wong C, Goh C, Cheung YB. Lee CF, et al. Among authors: wong c, wong ns. Support Care Cancer. 2013 Jan;21(1):201-9. doi: 10.1007/s00520-012-1512-x. Epub 2012 Jun 6. Support Care Cancer. 2013. PMID: 22669608

8

Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.

Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M. Verma S, et al. Among authors: wong ns. Am J Clin Oncol. 2007 Jun;30(3):297-302. doi: 10.1097/01.coc.0000258125.97090.3f. Am J Clin Oncol. 2007. PMID: 17551309

9

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Wong NS, et al. J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026801 Clinical Trial.

10

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT. Yap YS, et al. Among authors: wong ns. JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269. JAMA Oncol. 2017. PMID: 28715540 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page